Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                Drug Safety and Availability

Drug Safety and Availability

                        Drug Alerts and Statements
          Information about Nitrosamine Impurities in Medications
          Medication Guides
          Drug Safety Communications


                        Food and Drug Administration Overdose Prevention Framework
          Drug Shortages
          FDA Drug Safety Podcasts
          Information by Drug Class
          Medication Errors Related to CDER-Regulated Drug Products
          Postmarket Drug Safety Information for Patients and Providers
          Risk Evaluation and Mitigation Strategies | REMS
          Safe Use Initiative
          Drug Recalls
          Drug Supply Chain Integrity
          Multistate outbreak of fungal meningitis and other infections Home
          Drugs
          Drug Safety and Availability
          FDA requires updates to labeling for promethazine hydrochloride injection productsDrug Safety and Availability FDA requires updates to labeling for promethazine hydrochloride injection products
  
  	
    Share
    Post
    Linkedin

    Email
    Print**[12/27/2023]** FDA is alerting health care professionals of labeling updates intended to further reduce the risk of severe chemical irritation and damage to tissues from intravenous administration of promethazine hydrochloride injection.

Promethazine hydrochloride injection is indicated to help manage certain allergic reactions, motion sickness, post-operative nausea and vomiting, and as a sedative or adjunct to analgesics.

FDA recommends health care professionals administer promethazine hydrochloride injection by deep intramuscular administration instead of intravenous administration. If promethazine hydrochloride injection must be administered intravenously, health care professionals should review and follow the updated information in the labeling to dilute promethazine hydrochloride injection and administer by intravenous infusion to reduce the risk of severe tissue injury.

FDA has required that manufacturers update their prescribing information for promethazine hydrochloride injection to include new safety information and update the carton labeling and container labels with the corresponding information.

If intramuscular injection is not possible, promethazine hydrochloride injection:

Can be administered intravenously only after dilution, as recommended, and infused through an intravenous catheter inserted in a large vein and preferably through a central venous catheter. Do not administer using intravenous catheters placed into veins in the hand or wrist.
	Should not be mixed with other drugs or diluted with solutions other than 0.9% sodium chloride injection.
	Is contraindicated for intravenous injection at concentrations greater than 1 mg/mL.When diluting and administering promethazine hydrochloride injection by intravenous infusion, infuse over 20 to 40 minutes and follow the below preparation and infusion instructions in adult and pediatric patients (see the first and second tables below, respectively):

**Table 1: Preparation and Infusion Information by Adult Dose of Promethazine Hydrochloride Injection**

Dose of Promethazine Hydrochloride Injection
			Volume of 0.9% Sodium Chloride Injection for Dilution
			Maximum Concentration of the Diluted Promethazine Hydrochloride Injection Solution
			Maximum Rate of Infusion12.5 mg
			50 mL
			1 mg/mL
			2.5 mL/minute25 mg
			50 mL
			2.5 mL/minute50 mg
			50 mL
			2.5 mL/minute75 mg
			100 mL
			5 mL/minute



**Table 2: Preparation and Infusion Information by Pediatric Dose of Promethazine Hydrochloride Injection**

Dose of Promethazine Hydrochloride Injection
			Volume of 0.9% Sodium Chloride Injection for Dilution
			Maximum Concentration of the Diluted Promethazine Hydrochloride Injection Solution
			Maximum Rate of InfusionUp to 25 mg
			25 mL
			1 mg/mL
			1.25 mL/minute25 mg to 50 mg
			50 mL

Health care professionals, caregivers, and patients should report adverse events or side effects related to the use of this product to FDA's MedWatch Safety Information and Adverse Event Reporting Program:

Complete and submit the report online at MedWatch Online Voluntary Reporting Form, or;
	Download and complete the form, then submit it via fax at 1-800-FDA-0178.

                                                                                  Content current as of:
      12/27/2023Drug Safety and Availability

          
                        Drug Alerts and Statements
          Information about Nitrosamine Impurities in Medications
          Medication Guides
          Drug Safety Communications


                        Food and Drug Administration Overdose Prevention Framework
          Drug Shortages
          FDA Drug Safety Podcasts
          Information by Drug Class
          Medication Errors Related to CDER-Regulated Drug Products
          Postmarket Drug Safety Information for Patients and Providers
          Risk Evaluation and Mitigation Strategies | REMS
          Safe Use Initiative
          Drug Recalls
          Drug Supply Chain Integrity
          Multistate outbreak of fungal meningitis and other infections
 
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop